Table 1. Clinical and biological characteristics of CLL cases.
Variable | Category | CLL cases (n = 80) |
---|---|---|
Age at diagnosis | ||
Median (range) | 58.7 (37-80) | |
Gender (F/M) | ||
Female | 22 (27.5%) | |
Male | 58 (72.5%) | |
Percentage of tumor cells | ||
Median (range) | 97 (64-99) | |
Rai stage | ||
0 | 38 (47.50%) | |
I | 12 (15%) | |
II | 18 (22.5%) | |
III | 5 (6.25%) | |
IV | 7 (8.75%) | |
Binet stage | ||
A | 51 (63.75%) | |
B | 18 (22.5%) | |
C | 11 (13.75%) | |
Previous treatment | ||
Untreated | 68 (85%) | |
Treated | 12 (15%) | |
IGVH status | ||
Mutated | 46 (57.5%) | |
Unmutated | 33 (41.25%) | |
Not evaluated | 1 (1.25%) | |
ZAP-70 expression | ||
ZAP-70− | 57 (71.25%) | |
ZAP-70+ | 22 (27.5%) | |
Not evaluated | 1 (1.25%) | |
CD38 expression | ||
CD38− | 61 (76.25%) | |
CD38+ | 18 (22.5%) | |
Not evaluated | 1 (1.25%) | |
CD49d expression | ||
CD49d− | 15 (18.75%) | |
CD49d+ | 46 (57.5%) | |
Not evaluated | 19 (23.75%) | |
Cytogenetics | ||
Deletion of 17p | 2 (2.5%) | |
Trisomy 12 | 8 (10%) | |
Deletion of 13q | 44 (55%) | |
Deletion of 11q | 10 (12.5%) | |
Normal | 20 (25%) | |
Not evaluated | 1 (1.25%) | |
Recurrent mutations | ||
ATM | 7 (8.75%) | |
SF3B1 | 5 (6.25%) | |
NOTCH1 | 4 (5%) | |
MYD88 | 2 (2.5%) | |
TP53 | 4 (5%) |